Examining the Use of Checkpoint Inhibitors in Bladder Cancer Thursday, December 5, 2019 Renaissance Capital Ballroom Washington, DC More information and registration Speakers Robert Dreicer, MD, MS, MACP, FASCO University of Virginia School of Medicine Charlottesville, Virginia Dr. Dreicer is the Associate Director for Clinical Research and the Deputy Director
Join the John Wayne Cancer Institute and BCAN on November 9th from 10 AM to 2 PM for their Lunch and Learn. Free lunch is provided, registration required. The agenda includes: 10:00am – 10:10am | Introduction to Symposium – Jennifer Linehan, MD 10:10am – 10:30am | Basics, Risk Factors and
Co-sponsored by the: U.S. Food and Drug Administration (FDA) and the Bladder Cancer Advocacy Network (BCAN) Date: Thursday, August 8, 2019 from Noon-4PM EST Location: Capital Hilton, 1001 16th Street NW, Washington, DC 20036 Cost: Free – WebEx Only Neoadjuvant cisplatin-based combination chemotherapy followed by radical cystectomy is a standard
BCAN is pleased to work with local hosptials and physician groups to bring bladder cancer programs to your community. Known as Lunch & Learn Live! each unique program reflects the needs and showcases the resources available locally. Objectives 1) To increase patient understanding of the risks, diagnosis, staging and treatment
Click below to learn more about our
Survivor to Survivor program that matches
newly diagnosed bladder cancer patients with survivors.